Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis
- PMID: 15562880
- DOI: 10.1016/S1081-1206(10)61408-1
Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis
Abstract
Background: Sublingual swallow immunotherapy has been increasingly recognized as a safe and efficacious alternative to parenteral specific immunotherapy.
Objective: To determine the safety and efficacy of sublingual swallow immunotherapy ragweed allergen extract for rhinoconjunctivitis treatment starting just before and continuing through the ragweed pollen season.
Methods: This randomized, double-blind, placebo-controlled study was performed in children and adults with a documented history of allergic rhinoconjunctivitis during ragweed season at 9 Canadian allergy centers. Active treatment was standardized extract of ragweed allergen administered as sublingual swallow drops at increasing doses starting shortly before the pollen season and maintenance doses continued daily during the season. Primary efficacy variables were symptom and medication scores, and secondary variables included global evaluation of efficacy and immunologic measurements.
Results: Eighty-three patients were included in the safety analysis; 76 patients were included in the intent-to-treat analysis. Nine placebo recipients and 1 treatment recipient withdrew for lack of efficacy (P = .004). Nine patients in the treatment group withdrew because of adverse events, none serious (P = .003). Investigator evaluation of efficacy showed that significantly more patients improved and fewer deteriorated in the treatment group vs the placebo group (P = .047). Ragweed IgE and IgG4 levels increased significantly in treatment recipients vs placebo users (P < .001). Sneezing and nasal pruritus approached significant improvement in the treatment group vs the placebo group (P = .09 and .06, respectively). Quebec City experienced low pollen counts. Excluding Quebec City, significant improvement was seen for these 2 symptoms (P = .04).
Conclusion: Sublingual swallow immunotherapy seems to be safe and efficacious for ragweed rhinoconjunctivitis even when started immediately before the ragweed pollen season.
Comment in
-
Sublingual swallow immunotherapy in the new world.Ann Allergy Asthma Immunol. 2004 Nov;93(5):405-6. doi: 10.1016/S1081-1206(10)61404-4. Ann Allergy Asthma Immunol. 2004. PMID: 15562876 No abstract available.
Similar articles
-
Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen.J Allergy Clin Immunol. 2010 Mar;125(3):660-6, 666.e1-666.e4. doi: 10.1016/j.jaci.2009.12.931. Epub 2010 Feb 11. J Allergy Clin Immunol. 2010. PMID: 20153030 Clinical Trial.
-
Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.J Allergy Clin Immunol. 2006 Apr;117(4):802-9. doi: 10.1016/j.jaci.2005.12.1358. J Allergy Clin Immunol. 2006. PMID: 16630937 Clinical Trial.
-
Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen.J Allergy Clin Immunol. 2014 Jan;133(1):121-9.e1-2. doi: 10.1016/j.jaci.2013.05.032. Epub 2013 Jul 16. J Allergy Clin Immunol. 2014. PMID: 23870670 Clinical Trial.
-
Ragweed sublingual tablet immunotherapy: part I - evidence-based clinical efficacy and safety.Immunotherapy. 2018 Jun;10(7):605-616. doi: 10.2217/imt-2017-0186. Epub 2018 Apr 10. Immunotherapy. 2018. PMID: 29634392 Review.
-
300IR 5-Grass pollen sublingual tablet offers relief from nasal symptoms in patients with allergic rhinitis.Am J Rhinol Allergy. 2014 Nov-Dec;28(6):471-6. doi: 10.2500/ajra.2014.28.4112. Epub 2014 Oct 20. Am J Rhinol Allergy. 2014. PMID: 25335122 Review.
Cited by
-
Consensus Guidelines on Practical Issues of Immunotherapy-Canadian Society of Allergy and Clinical Immunology (CSACI).Allergy Asthma Clin Immunol. 2006 Jun 15;2(2):47-61. doi: 10.1186/1710-1492-2-2-47. Epub 2006 Jun 15. Allergy Asthma Clin Immunol. 2006. PMID: 20525157 Free PMC article.
-
Challenges and Future Prospects for the Delivery of Biologics: Oral Mucosal, Pulmonary, and Transdermal Routes.AAPS J. 2017 May;19(3):652-668. doi: 10.1208/s12248-017-0054-z. Epub 2017 Feb 13. AAPS J. 2017. PMID: 28194704
-
Sub-lingual immunotherapy: world allergy organization position paper 2009.World Allergy Organ J. 2009 Nov;2(11):233-81. doi: 10.1097/WOX.0b013e3181c6c379. Epub 2009 Nov 19. World Allergy Organ J. 2009. PMID: 23268425 Free PMC article. No abstract available.
-
Clinical immunology review series: an approach to desensitization.Clin Exp Immunol. 2011 Feb;163(2):131-46. doi: 10.1111/j.1365-2249.2010.04296.x. Epub 2010 Dec 22. Clin Exp Immunol. 2011. PMID: 21175592 Free PMC article. Review.
-
Brazilian guidelines for allergen immunotherapy in the treatment of allergic rhinitis.Rev Assoc Med Bras (1992). 2023 Jun 2;69(5):e2023D695. doi: 10.1590/1806-9282.2023D695. eCollection 2023. Rev Assoc Med Bras (1992). 2023. PMID: 37283333 Free PMC article. No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical